PTIXW
Income statement / Annual
Last year (2023), Protagenic Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Protagenic Therapeutics, Inc.'s net income was -$5.00 M.
See Protagenic Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
06/30/2015 |
06/30/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$28,218.00 |
$30.00 |
$0.00 |
$286.00 |
$339.00 |
$347.00 |
$148.00 |
$534.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$28,218.00 |
-$30.00 |
$0.00 |
-$286.00 |
-$339.00 |
-$347.00 |
-$148.00 |
-$534.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$3.32 M
|
$1.59 M
|
$1.14 M
|
$699,797.00
|
$807,947.00
|
$881,186.00
|
$717,452.00
|
$417,866.00
|
$464.46
|
$42,000.00
|
| General & Administrative
Expenses |
$1.21 M
|
$1.97 M
|
$3.00 M
|
$1.85 M
|
$1.28 M
|
$1.43 M
|
$1.65 M
|
$1.30 M
|
$491,000.00
|
$975,000.00
|
| Selling & Marketing
Expenses |
-$28,218.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$115,827.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$1.21 M
|
$1.97 M
|
$3.00 M
|
$1.85 M
|
$1.28 M
|
$1.43 M
|
$1.65 M
|
$1.41 M
|
$491,000.00
|
$975,000.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$404,169.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$4.53 M |
$3.56 M |
$4.14 M |
$2.55 M |
$2.09 M |
$2.31 M |
$2.37 M |
$1.83 M |
$491,000.00 |
$975,000.00 |
| Cost And Expenses |
$4.53 M |
$3.56 M |
$4.14 M |
$2.55 M |
$2.09 M |
$2.31 M |
$2.37 M |
$1.83 M |
$491,000.00 |
$975,000.00 |
| Interest Income |
$264,476.00 |
$185,790.00 |
$33,207.00 |
$502.00 |
$2,813.00 |
$2,790.00 |
$13,890.00 |
$907.00 |
$0.00 |
$0.00 |
| Interest Expense |
-$107,682.00 |
$137,456.00 |
$496,912.00 |
$246,178.00 |
$15,886.00 |
$2,790.00 |
$13,890.00 |
$7,162.00 |
$18,000.00 |
$3,000.00 |
| Depreciation &
Amortization |
$28,218.00
|
$30.00
|
$286.00
|
$286.00
|
$339.00
|
$347.00
|
$148.00
|
$534.00
|
$1,000.00
|
$0.38
|
| EBITDA |
-$4.50 M
|
-$3.37 M
|
-$4.11 M
|
-$2.55 M
|
-$2.08 M
|
-$2.07 M
|
-$2.35 M
|
-$1.83 M
|
-$490,000.00
|
-$975,000.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$473,523.00
|
$2,283.00
|
-$382,521.00
|
$2,876.00
|
$335,219.00
|
-$246,194.00
|
$91,798.00
|
-$440,239.00
|
$8,000.00
|
$54,000.00
|
| Income Before Tax |
-$5.00 M |
-$3.56 M |
-$4.52 M |
-$2.55 M |
-$1.75 M |
-$2.56 M |
-$2.26 M |
-$2.28 M |
-$501,000.00 |
-$924,000.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$2.00 |
$46,051.00 |
$463,705.00 |
$246,178.00 |
$15,886.00 |
$486,808.00 |
-$105,688.00 |
$440,239.00 |
-$33,000.00 |
$101,000.00 |
| Net Income |
-$5.00 M |
-$3.60 M |
-$4.99 M |
-$2.79 M |
-$1.77 M |
-$2.56 M |
-$2.26 M |
-$2.28 M |
-$476,000.00 |
-$1.08 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.15 |
-0.83 |
-1.35 |
-1.08 |
-0.69 |
-1 |
-0.88 |
-1.72 |
-73.23 |
-166.86 |
| EPS Diluted |
-1.15 |
-0.83 |
-1.35 |
-1.08 |
-0.69 |
-1 |
-0.88 |
-1.72 |
-73.23 |
-166 |
| Weighted Average Shares
Out |
$4.34 M
|
$4.32 M
|
$3.69 M
|
$2.58 M
|
$2.57 M
|
$2.57 M
|
$2.57 M
|
$1.33 M
|
$6,500.00
|
$6,466.63
|
| Weighted Average Shares
Out Diluted |
$4.34 M
|
$4.32 M
|
$3.69 M
|
$2.58 M
|
$2.57 M
|
$2.57 M
|
$2.57 M
|
$1.33 M
|
$6,500.00
|
$6,500.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
